PatrĂ­cia Silva, PhD, director of science content —

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

FDA Approves Third Generation Nebulizer for Tyvaso Inhalation System

The U.S. Food and Drug Administration (FDA) has approved a new, third-generation inhalation device, the TD-300/A, for use with Tyvaso (treprostinil) Inhalation Solution, United Therapeutics Corporation announced. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. Tyvaso was…

Reviva-FDA Meeting Paves Way for Phase 2 Clinical Trial of RP5063 as a PAH Therapy

Reviva Pharmaceuticals has had a meeting with the U.S. Food and Drug Administration that paves the way for a Phase 2 clinical trial of its neurodegenerative therapy RP5063 in pulmonary arterial hypertension. The meeting dealt with an investigational new drug application the company will submit on RP5063. What is known in therapy development circles…

New Model of Intensive Care Breathing Specialists Working with Heart Doctors Is Promising, Study Reports

Doctors who are intensive care respiratory specialists help seriously ill heart patients with breathing difficulties achieve better outcomes, a University of Maryland School of Medicine study reports. Researchers said the new model of having these specialists work with cardiac specialists also lowers patients’ costs. One reason the model works is that…

PHA Expands Network of Centers for Comprehensive Care

The Pulmonary Hypertension Association (PHA) has expanded its Pulmonary Hypertension Care Centers (PHCC) network by accrediting two new pulmonary hypertension (PH) programs as Centers for Comprehensive Care (CCC). The two new additions, the Pulmonary Hypertension Programs at Cincinnati Children’s Hospital Medical Center, in Cincinnati, Ohio, and…

What to Know About Pulmonary Hypertension and Depression

According to the Pulmonary Hypertension Association, depression can happen to anyone, in fact, health care professionals believe that we will all experience depression at some point in our lives. However, living with pulmonary hypertension can introduce factors into our daily lives that put patients at a higher risk of developing depression.

The Influence of Climate on Pulmonary Hypertension

Pulmonary hypertension (PH) is a disease that can easily be affected by certain climatic factors. It is important that patients are aware of these to help manage their disease in different environments. The Pulmonary Hypertension Association has some helpful information regarding how climate can affect pulmonary hypertension patients. MORE: Pulmonary…

Two Pulmonary Hypertension Groups Sign Up for ZappRx’s Streamlined Prescription-ordering Service

Two pulmonary hypertension treatment groups are now working with a company that helps doctors to streamline the complex process of obtaining insurance company sign-offs on speciality prescriptions, which can take weeks. Arizona Pulmonary Specialists in Phoenix and the pulmonary hypertension unit at Harbor-UCLA Medical Center in Torrance, California, have become clients of  ZappRx. The process…

Learn How the WHO Classifies Pulmonary Hypertension Cases

The World Health Organization has a pulmonary hypertension clinical classification system that was created in 2008 and updated the following year, where they divide the disease into five groups, sorted by cause, origin, incidence and prevalence. This classification system is used for death certificates, diagnosis, mortality statistics, records, and other purposes. MORE: …